8DZ Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.17K
Market Cap
€496.11K
Enterprise Value€1.32
Total Cash (Recent Filing)€60.85K
Total Debt (Recent Filing)€394.63K
Price to Earnings (P/E)―
Beta-3.74
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume3,500
30 Day Avg. Volume1,166
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Positive EquityModerate leverage and positive equity provide a more stable financial base than the company had in earlier periods. This reduces balance-sheet pressure and preserves some flexibility to fund operations, address losses, and pursue growth without relying entirely on additional borrowing.
Recently Positive Cash GenerationThe move from negative operating and free cash flow in FY2023–FY2024 to positive TTM generation is an important improvement in financial quality. If maintained, internally generated cash could reduce financing needs and support ongoing operations despite weak reported earnings.
Improved Gross Margin And Reduced EBITDA LossImproved gross margin indicates better economics on the company’s current sales base, while the smaller EBITDA loss suggests progress toward operating stabilization. Sustaining these gains would provide a foundation for stronger earnings if revenue contraction is eventually reversed.
Bears Say
Sharp Revenue ContractionShrinking revenue weakens operating leverage and makes it harder to absorb fixed costs, invest in the business, or convert margin improvements into meaningful earnings. Continued contraction would also reduce the scale available to support durable cash generation and profitability.
Persistent Losses And Negative ReturnsOngoing net and operating losses show that the business has not yet achieved a sustainable profit model. Negative returns on equity further indicate that shareholder capital is not currently generating value, limiting the company’s ability to build financial strength internally.
Modest And Weakening Free Cash FlowAlthough cash flow is currently positive, its decline from the prior period and modest conversion relative to revenue weaken confidence in its durability. Without revenue stabilization and lower operating losses, positive free cash flow may not persist through the next several quarters.
Pascal Biosciences Inc News
8DZ FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is €496.11K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 14 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in DE:8DZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―